ivergol Effect on Decrease of Hepatotoxicity caused by Chemotherapy Drugs
- Conditions
- Acute lymphoblastic leukaemia [ALL].
- Registration Number
- IRCT20170821035831N2
- Lead Sponsor
- rmia Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
ALL diagnosis based on the criteria of the International Institute of Cancer with initial involvement of more than 20% of bone marrow
Hepatotoxicity of Grade 2 and 3 in each of the following four cases based on the criteria of the International Institute of Cancer: Aminoalanine Transferase (ALT); Aspartate Aminotransferase (AST); Total Bilirubin (TB)
ALL patients in the chemotherapy maintenance phase.
ALL patients, 15-2 years old
Patients ALL Pre Bcell, Early Pre Bcell
Unwillingness to participate in the studyl
Extra bile duct obstruction, severe liver or kidney failure, gastrointestinal obstruction, malabsorption syndrome, viral hepatitis
Grade 4 hepatotoxicity
Sepsis-induced hepatotoxicity
Intolerance to Oral Fluoride
Deny the patient to study and continue taking the medication
No regular and daily intake of medication
Gastritis and other complications associated with taking Lourgal
History of allergy due to previous use of loroge
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver Enzyme (AST ALT Bill Total & Direct). Timepoint: Befor Intervention , 35 and 70 days after intervention. Method of measurement: Microgram Per Litrer(for Liver Enzyme) - Miligram Per Deciliter(for Billi).
- Secondary Outcome Measures
Name Time Method